ClinicalTrials.gg
CompletedNCT04327609SAVEUpdated Aug 29, 2025

SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications

An interventional study of SELUTION SLR™ DEB and Control Arm in AV Fistula, sponsored by M.A. Med Alliance S.A.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Prospective multi-center single-blinded randomized controlled trial (RCT) investigating the safety and feasibility of the SELUTION SLR™ (Sustained Limus Release) 018 drug eluting balloon (DEB) for the treatment of failed AV fistula in renal dialysis patients. Patients will be randomised to either SELUTION SLR or POBA.

02

Conditions studied

  • AV Fistula

Browse trials for

03

In context

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

This study's enrollment of 84 is above the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.

Browse Arteriovenous Fistula studies →

Lead sponsor

M.A. Med Alliance S.A. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-90 years
  • Patient is able and willing to provide written
  • A Dialysis Access that has performed at least 1 successful dialysis session
  • Stenosis >50% at the outflow vein (by visual estimation) with clinical circuit dysfunction
  • Lesion of ≤7mm in diameter
  • Lesion of up to the 70mm in length

Exclusion criteria

Exclusion Criteria:

  • \<1year
  • Lower extremity AVG
  • Infected AVG
  • Uncontrolled systemic infection
  • Aneurysm or pseudoaneurysm in proposed target lesion
  • Presence of previous CS or BMS
  • ≥2 lesions present within the circuit
  • Unable to perform protocol prescribed pre-dilation of the lesion
  • Patient is female and is pregnant, or planning to become pregnant during the course of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    SELUTION SLR™ DEB

    Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.

    Device: SELUTION SLR™ DEB

  • Active comparator
    Control Treatment

    POBA

    Device: Control Arm

Interventions

  • DeviceSELUTION SLR™ DEB

    Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.

  • DeviceControl Arm

    The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.

06

What researchers measure

Primary outcomes

  1. Primary Patency of the treated lesion at 6 months post-intervention.

    Primary patency: Defined as uninterrupted patency after the initial intervention with regular ongoing dialysis until symptomatic recurrent stenosis of the dialysis circuit, or thrombosis, mandating repeat treatment, or further surgical intervention of the access circuit or eventual failure/abandonment of the circuit with creation of alternative access for dialysis. This endpoint will be analysed cumulatively at 6 months and with time-to-event methods (e.g. Kaplan Meier) on extended follow-up period to 2 years.

    Time frame: 6 months

  2. Freedom from any serious adverse event(s) involving the AV access circuit or the patient at 30 days

    Freedom from any serious adverse event(s) involving the AV access circuit or the patient at 30 days.

    Time frame: 30 days

Secondary outcomes

  1. Freedom from any serious adverse event(s) involving the AV access circuit or the patient at 6 months.

    Freedom from any serious adverse event(s) involving the AV access circuit or the patient at 6 months.

    Time frame: 6 months

  2. Late lumen loss

    Late lumen loss (LLL) defined as the difference between the minimum lumen diameters after angioplasty and at the end of the 6-month follow-up angiogram.

    Time frame: 6 months

  3. Device Success

    Device Success: Defined as successful balloon inflation of the SELUTION catheter for ≥2 minutes and retrieval of the catheter.

    Time frame: During Procedure

  4. Anatomic success

    Anatomic success: Defined as \<30% residual stenosis diameter measured immediately after angioplasty.

    Time frame: Immediately after angioplasty

  5. Clinical Success

    Clinical Success: Defined as an improvement from baseline in the clinical or hemodynamic parameter (e.g., blood flow, venous pressures) that was the initial indicator of fistula dysfunction and the resumption of normal hemodialysis for a minimum of at least 1 session following the procedure.

    Time frame: 6 months

  6. Binary Vessel Restenosis

    Binary vessel restenosis: Angiographic restenosis rate defined as the incidence of stenosis ≥50% of the diameter of the reference vessel segment within the treated target lesion.

    Time frame: 6 months

07

Study locations

3 sites
  • University of Athens
    Athens, Greece
  • University of Patras
    Pátrai, Greece
  • Singapore General Hospital LTD
    Singapore, Singapore
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Feb 2024, 45 months.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Mar 31, 2020
StartActual
Apr 10, 2020
Primary completionActual
Feb 1, 2024
CompletionActual
Jul 23, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04327609
Lead sponsor
M.A. Med Alliance S.A.
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Apr 10, 2020
Primary completion
Feb 1, 2024
Completion
Jul 23, 2025
Last update
Aug 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion